The existence of tumour-specific antigens has long been questioned, but recently the first tumour rejection antigen was identified and cloned from a human malignant melanoma (van der Bruggen et al., 1991) . Several groups have demonstrated autologous tumour-reactive, MHC-restricted tumourinfiltrating T lymphocytes (TILs) derived from malignant melanomas (Herin et al., 1987; Itoh et al., 1988) , and similar results have been obtained with TILs from head and neck cancers (Yasumura et al., 1993) and ovarian carcinomas (Ioannides et al., 1993) . In vivo, TILs appear to be more effective in adoptive immunotherapy than autologous peripheral blood lymphocytes (PBLs) (Rosenberg et al., 1988) , suggestive of a primed population in the tumour area. Few studies are available on TILs from colorectal carcinomas, but a recent report provides evidence for a specific, MHC-restricted immune response to autologous, human colon carcinomas (Hom et al., 1993) . Furthermore, the degree of lymphoid infiltration in such tumours is strongly correlated with the prognosis (Svennevig et al., 1984; Jass, 1986) , suggesting that patients can raise a significant immune response against these tumours.
Finally, gene transfection studies in murine models have shown that provision of local help in the form of cytokines (Fearon et al., 1990; Golumbek et al., 1992) can induce tumour rejection both locally and distantly, and can even enable the immune system to reject a later challenge with unmodified (parental) tumour cells.
Thus, a specific immune response can be mounted against at least some tumours, although insufficient or abrogated in most cases. Conventional phenotyping of freshly isolated TILs has shown that the infiltrating cells are predominantly T cells, which are activated and express the memory phenotype (CD45R0+) more often than peripheral blood lymphocytes from the same patient (Topalian et al., 1987; Ostenstad et al., 1994) .
If T cells do recognise and react to tumour-specific antigens, a clonal expansion of the tumour-reactive T cells is expected to be an early event. A clonal expansion of this kind will be characterised by restricted T-cell receptor (TCR) variable region gene (V-gene) (Ibrahim et al., 1993) and autoimmune diseases (Sioud et al., 1992; Davies et al., 1993) . Limited heterogeneity has also been demonstrated in IL-2-expanded TILs (Karpati et al., 1991; Morita et al., 1992) . However, the VP repertoire is influenced by mitogen stimulation in vitro (Wong et al., 1993) (Nitta et al., 1991; Ferradini et al., 1993) and hepatocellular carcinomas (Weidmann et al., 1992) , while other reports conclude that the immune response to tumour is extremely diverse, with no preferential usage of any gene (Ferradini et al., 1992 One million cells from each compartment were frozen as pellets for later extraction of total RNA.
Phenotyping
Freshly isolated lymphocytes were suspended in cold HBSS containing 0.02% sodium azide in V-bottom plates. Fluorescein-conjugated monoclonal antibodies were added in 1:20 dilutions for staining 30 min on ice. The following antibodies were used: UCHT-1 (anti-CD3), MT310 (anti-CD4), DK25 (anti-CD8), HD37 (anti-CD19), UCHL-1 (anti-CD45R0), ACT-1 (anti-CD25), HLA-DR CR3/43 (reacting with the common MHC class II P-chain) (all from Dako, Glostrup, Denmark), and 2H4 (anti-CD45RA) and NKH-1 (anti-CD56) (from Coulter Immunology, Hialeah, FL, USA).
Analysis was performed using a FACScan flow cytometer (Beckton Dickinson, Mountain View, CA, USA) and LYSYS II software.
Preparation of RNA, cDNA synthesis and polymerase chain reaction (PCR) amplification Total RNA was prepared using guanidium isothiocyanatephenol-chloroform extraction (Chomczynski & Sacchi, 1987) . cDNA was synthesised from RNA as described previously (Sioud et al., 1991) . The same amount of cDNA from each sample was used as template for PCR amplification using a panel of 19 family-specific oligonucleotides and Cp-primers with sequences as previously described (Sioud et al., 1991) .
The scope of this investigation was a non-quantitative search for the relative overrepresentation of certain Vpfamilies within each tumour, and each sample therefore served as its own control. However, in order to be sure that all the different reactions were set up with the same accuracy, we also performed co-amplification of the constantly present Ca-segment in a few samples. The sense and antisense Caprimers used were as described previously (Sioud et al., 1991) . Thirty to forty amplification cycles were performed using a DNA thermal cycler (Perkin Elmer, Cetus). Each cycle consisted of denaturation at 92°C for 1 min, annealing at 56°C for 1+ min and extension at 72°C for 2+ min. The PCR products were separated on a 2% agarose gel, transferred to nylon membrane, hybridised with 5' 32P-labelled internal Cp- (Figures 1 and 2) . In TIL 17 only one VP-family was detected, as indicated by the arrow. This is strongly suggestive of an overrepresentation of V,3 within this sample. Remarkably, this same family is absent from the corresponding PBLs (Table II) . In TIL 20, four families are detected, consistent with an overexpression of these families within the sample.
Our method is only semiquantitative, and comparison between two samples is difficult. However, if we look at 
Discussion
Much evidence has accumulated during the past few years supporting the hypothesis of a specific immune response against malignant tumours. However, most studies so far have focused on the functional testing of T-cell cytotoxicity (Herin et al., 1987; Itoh et al., 1988; Yasumura et al., 1993) or cytokine secretion (Belldegrun et al., 1989; Hom et al., 1993 The fact that different sets of families predominate in each tumour therefore argue against a biased amplification due to variable quality of the primers. The inter-sample variability may actually serve as internal controls.
That no single family is consistently overrepresented in all the tumours may reflect the complexity of the TCR-antigen interaction. T cells (presumably including TILs) recognise antigens in the form of short peptides presented in the context of MHC molecules on the target cell. These peptides may be fragments of mutated gene products in the tumour cell having a unique sequence. The specific interaction between tumour cells and T lymphocytes therefore depends on the presence of immunogenic peptides, suitable antigenpresenting MHC molecules and the specific T-cell receptor (TCR).
The variable pattern of gene usage may be explained by the accumulation of mutations in colorectal tumours (Fearon & Vogelstein, 1992) , which may give rise to a number of hypothetical T-cell antigens. Any antigenic peptide may also be more or less well presented in different patients depending on their HLA type and individual expression of MHC molecules. Thus, several antigen-MHC combinations may be present in one tumour, although the host usually responds to only one of several antigens displayed simultaneously on the tumour cell surface (immunodominant epitopes) (Urban et al., 1986) .
Finally, both tumour-specific effectors and negative regulatory T-cell clones may coexist in the same tumour, as suggested by specific VP-depletion studies (Gelber et al., 1992) . These different subsets may express receptors belonging to different VP-families.
With this complexity in mind, we note that in three out of seven patients there was definitely an oligoclonal pattern, with fewer than five families clearly represented. To the best of our knowledge this is demonstrated here in TILs from colorectal cancers for the first time.
A limited heterogeneity was also noted in the rest of the patients, comparing TILs with PBLs. However, the repertoire in these four patients was nearly as heterogenous as in the four control samples from tumour-free LPLs. We had expected a more polyclonal pattern among LPLs. One possible explanation is that this may be caused by a predominant non-specific inflammatory response in the neighbouring area.
In TIL 11 and 16 (and to somne extent in TIL 21 and 22) such an inflammatory response may obscure a possible specific oligoclonality. It is noteworthy, however, that in one of the paired LPL/TIL samples (16) V,4, VP6, VP9 and VP I11 were present in TILs, but not in LPLs. In another matched pair (21) VP5 and VP15 were present in TILs, while absent in LPLs. This is also suggestive of possible tumour-reactive clones.
Taken together, a limited heterogeneity in the VP-gene usage was found among TILs, consistent with an expansion of tumour-reactive clones in situ. No single predominant VP-family was detected in the present tumours, suggesting the involvement of different antigen-MHC combinations. Sequence analysis of the fine specificity in the junctional region may clarify this point.
To better understand the significance of this apparent restriction, it is necessary to combine this approach of TCR phenotyping with functional studies at the clonal level.
Monoclonal antibodies against a number of different Vpfamilies are now available. In contrast to the PCR approach, such antibodies can be utilised in the detection and sorting of viable cells for functional studies, and possibly also in future for selection of T cells particularly suited for adoptive immunotherapy. Alternatively, putative suppressor clones can be depleted.
In conclusion, this study supports the hypothesis that tumour-specific T lymphocytes reside and expand in the tumour area, although the response may be directed against different antigens.
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